Abstract
We report a case of a 59-year-old woman with metastatic carcinoma of the ileocecal region who received FOLFOX(oxaliplatin/leucovorin/5-fluorouracil) and bevacizumab therapy and exhibited a partial remission with minimal side effects. She developed a mild self-limited episode of immune-mediated hemolytic anemia during her 16th cycle of chemotherapy, which precluded her from receiving further oxaliplatin. We review the literature on oxaliplatin-induced immune-mediated hemolysis, including its mechanism, presenting symptoms, laboratory features, management, and implications for future therapy.
MeSH terms
-
Anemia, Hemolytic / chemically induced*
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bevacizumab
-
Cecal Neoplasms / drug therapy
-
Drug Hypersensitivity / etiology*
-
Female
-
Fluorouracil / therapeutic use
-
Humans
-
Hypersensitivity, Delayed / chemically induced*
-
Ileal Neoplasms / drug therapy
-
Intestinal Neoplasms / drug therapy*
-
Leucovorin / therapeutic use
-
Middle Aged
-
Organoplatinum Compounds / adverse effects*
-
Organoplatinum Compounds / therapeutic use
-
Oxaliplatin
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Organoplatinum Compounds
-
Oxaliplatin
-
Bevacizumab
-
Leucovorin
-
Fluorouracil